共 50 条
- [45] A phase 1 study of PARP-inhibitor ABT-767 in advanced solid tumors with BRCA1/2 mutations and high-grade serous ovarian, fallopian tube, or primary peritoneal cancer Investigational New Drugs, 2018, 36 : 828 - 835
- [48] Part I of GANNET53: A multicenter phase I/II trial of the Hsp90 inhibitor ganetespib (G) combined with weekly paclitaxel (P) in women with high-grade serous, high-grade endometrioid, or undifferentiated, platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
- [49] Case 11-2006: A 54-year-old woman with a mass in the pelvis - Mixed high-grade serous papillary and transitional-cell carcinoma of the fallopian tube, FIGO stage IIIC. NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (15): : 1615 - 1625
- [50] A multicenter phase II study of the efficacy and safety of quisinostat (an HDAC inhibitor) in combination with paclitaxel and carboplatin chemotherapy (CT) in patients (pts) with recurrent platinum resistant high grade serous epithelial ovarian, primarily peritoneal or fallopian tube carcinoma cancer (OC). JOURNAL OF CLINICAL ONCOLOGY, 2017, 35